The medications sold under the brand names Ozempic and Wegovy are among them
With both injectable and oral formulations available, patients have the flexibility to choose a method that best fits their lifestyles
Wegovy is currently only approved for obesity, while Ozempic and Mounjaro are FDA-approved for type 2 diabetes treatment
Apart from modern technologies of targeted fat loss or surgical operations, no diet or weight loss drug can be directed to only one area of the body (for example, the face), so the same changes can happen in other areas we call this the Ozempic body
For professionals in generics, biotech, or investment, the implications are profound: Generics Industry: Mylans success paves the way for other manufacturers, potentially lowering costs for patients and increasing competition
*If medically eligible